HYPOTHYROIDISM DURING ONCOLOGY PROTOCOLS: A REPORT ON THREE CASES

Fuente: Zenodo
Salvato in:
Dettagli Bibliografici
Autori principali: Rania Dassoufi, Lahoucine Abainou, El Jadi Hamza , Azzelarab Meftah and Hicham Baizri
Natura: Recurso digital
Pubblicazione: Zenodo 2025
Soggetti:
Accesso online:
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
_version_ 1866901699720904704
author Rania Dassoufi
Lahoucine Abainou
El Jadi Hamza , Azzelarab Meftah and Hicham Baizri
author_facet Rania Dassoufi
Lahoucine Abainou
El Jadi Hamza , Azzelarab Meftah and Hicham Baizri
contents <div> <div> <div> <p><strong>Introduction:</strong>Hypothyroidism is commonly associated with different types of chemotherapy and immunotherapy. However, it remains largely unexplored, untreated, and is often neglected. We have reported 3 cases in order to highlight this endocrine consequence</p> <p><strong>Cases Report: </strong>The first two cases we reported were carriers of autoimmune thyroiditis with radio-biological confimation responsible for hypothyroidism. The first of them was followed up for colorectal carcinoma under chemotherapy with 5Fluorouracil based molecules and platinum drugs, the second case for metastatic pulmonary adenocarcinoma under immuno-chemotherapy: bevacizumab, paclitaxel and carboplatin. However, the last patient presented with hypothyroidism due to thyroid atrophy with negative immunological work-up, and was being treated for cavitary neoplasia with cisplatin and doxorubicin.</p> <p><strong>Discussion and Conclusion:</strong>Cytotoxic effects of chemotherapy due to ribonucleic/desocyrubonucleic alteration, followed by cell apoptosis concerns tumour tissue, but also rapidly metabolising tissues such as the endocrine glands, and particularly thyroid cells, causing thyroid atrophy. In the other hand, immunomodulatory effects are responsible for thyroiditis. While immunotherapies involve cytotoxicity of T lymphocytes, classically resulting in hypothyroidism sometimes preceded by thyrotoxicosis, leading in all cases to induced hypothyroidism.</p> <p> </p> </div> </div> </div> <div> </div>
format Recurso digital
id zenodo_https___doi_org_10_21474_IJAR01_20297
institution Zenodo
language
publishDate 2025
publisher Zenodo
record_format zenodo
spellingShingle HYPOTHYROIDISM DURING ONCOLOGY PROTOCOLS: A REPORT ON THREE CASES
Rania Dassoufi
Lahoucine Abainou
El Jadi Hamza , Azzelarab Meftah and Hicham Baizri
Hypothyroidism Chemotherapy Immunotherapy
<div> <div> <div> <p><strong>Introduction:</strong>Hypothyroidism is commonly associated with different types of chemotherapy and immunotherapy. However, it remains largely unexplored, untreated, and is often neglected. We have reported 3 cases in order to highlight this endocrine consequence</p> <p><strong>Cases Report: </strong>The first two cases we reported were carriers of autoimmune thyroiditis with radio-biological confimation responsible for hypothyroidism. The first of them was followed up for colorectal carcinoma under chemotherapy with 5Fluorouracil based molecules and platinum drugs, the second case for metastatic pulmonary adenocarcinoma under immuno-chemotherapy: bevacizumab, paclitaxel and carboplatin. However, the last patient presented with hypothyroidism due to thyroid atrophy with negative immunological work-up, and was being treated for cavitary neoplasia with cisplatin and doxorubicin.</p> <p><strong>Discussion and Conclusion:</strong>Cytotoxic effects of chemotherapy due to ribonucleic/desocyrubonucleic alteration, followed by cell apoptosis concerns tumour tissue, but also rapidly metabolising tissues such as the endocrine glands, and particularly thyroid cells, causing thyroid atrophy. In the other hand, immunomodulatory effects are responsible for thyroiditis. While immunotherapies involve cytotoxicity of T lymphocytes, classically resulting in hypothyroidism sometimes preceded by thyrotoxicosis, leading in all cases to induced hypothyroidism.</p> <p> </p> </div> </div> </div> <div> </div>
title HYPOTHYROIDISM DURING ONCOLOGY PROTOCOLS: A REPORT ON THREE CASES
topic Hypothyroidism Chemotherapy Immunotherapy
url https://doi.org/10.21474/IJAR01/20297